Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...

But without much media fanfare, the U.S. has recently experienced a boomlet in good health news. In May 2024, the U.S.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

After former City Manager Sheryl Sculley's exorbitant salary, bonuses and the ensuing kerfuffle with residents, city leaders ...

It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...

Tech mogul Elon Musk took to X/Twitter to reveal the secret behind his lean physique. In a festive post, Musk shared a photo ...

Apple has redefined what a watch can do. We talked to Apple’s top brains and other experts about the promises and perils of ...